Andrea Ardizzoni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7479329/publications.pdf

Version: 2024-02-01

72 papers	3,454 citations	218662 26 h-index	144002 57 g-index
73 all docs	73 docs citations	73 times ranked	5038 citing authors

#	Article	IF	Citations
1	Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System. American Journal of Clinical Dermatology, 2022, 23, 247-255.	6.7	18
2	A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stageÂsmall-cell lung cancer (CeLEBrATE study): background, design and rationale. Future Oncology, 2022, 18, 771-779.	2.4	3
3	Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. Targeted Oncology, 2022, 17, 43-51.	3.6	11
4	The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, 113.	8.6	9
5	Interobserver agreement of PD-L1 (SP263) assessment in advanced NSCLC on cytological smears and histological samples. Pathology Research and Practice, 2022, 233, 153893.	2.3	3
6	The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3107-e3114.	3.6	7
7	Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach. European Journal of Cancer, 2021, 143, 75-77.	2.8	7
8	Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Research and Treatment, 2021, 186, 219-227.	2.5	59
9	Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines, 2021, 9, 19.	4.4	11
10	Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer. , 2021, 9, e001865.		31
11	Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure. Anti-Cancer Drugs, 2021, Publish Ahead of Print, 755-757.	1.4	0
12	PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression â‰¥ 50%: Selecting the best strategy. Critical Reviews in Oncology/Hematology, 2021, 160, 103302.	4.4	18
13	Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System. Cancers, 2021, 13, 1758.	3.7	19
14	Bone fracture as a novel immuneâ€related adverse event with immune checkpoint inhibitors: Case series and largeâ€scale pharmacovigilance analysis. International Journal of Cancer, 2021, 149, 675-683.	5.1	11
15	Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches. Frontiers in Cell and Developmental Biology, 2021, 9, 666156.	3.7	12
16	MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary. Molecular Oncology, 2021, 15, 2732-2751.	4.6	14
17	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. EClinicalMedicine, 2021, 37, 100940.	7.1	11
18	Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis. JTO Clinical and Research Reports, 2021, 2, 100214.	1.1	3

#	Article	IF	Citations
19	Should we test cancer susceptibility genes in routinely used multigene panels? A case of synchronous lung adenocarcinoma and breast cancer associated with germline CHEK2 mutation. Clinical Lung Cancer, 2021, , .	2.6	2
20	Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis. Future Oncology, 2020, 16, 4409-4418.	2.4	54
21	The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia. Current Heart Failure Reports, 2020, 17, 365-383.	3.3	17
22	Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. Critical Reviews in Oncology/Hematology, 2020, 156, 103119.	4.4	97
23	Pulmonary adenocarcinoma with psammoma bodies is associated with a specific endobronchial ultrasound pattern and a high prevalence of actionable driver mutations. Lung Cancer, 2020, 147, 204-208.	2.0	2
24	CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592095299.	3.2	23
25	Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. Targeted Oncology, 2020, 15, 449-466.	3.6	86
26	The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?. Cancers, 2020, 12, 3129.	3.7	29
27	New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091380.	3.2	10
28	A Case of Response to Immunotherapy in a Patient With MSI Metastatic Colorectal Cancer and Autoimmune Disease Receiving Steroid Therapy. Journal of Immunotherapy, 2020, 43, 153-155.	2.4	4
29	Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 666.	3.7	24
30	First-line pembrolizumab in advanced nonâ€“small cell lung cancer patients with poor performance status. European Journal of Cancer, 2020, 130, 155-167.	2.8	98
31	CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. European Journal of Cancer, 2020, 127, 160-172.	2.8	112
32	Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL). British Journal of Cancer, 2020, 123, 26-32.	6.4	17
33	ECOG performance status â‰¥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitorsâ€”A systematic review and meta-analysis of real world data. Lung Cancer, 2020, 145, 95-104.	2.0	96
34	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. Expert Opinion on Biological Therapy, 2020, 20, 1047-1059.	3.1	9
35	Randomized Pilot Trial of Percutaneous Posterior Tibial Nerve Stimulation Versus Medical Therapy for the Treatment of Low Anterior Resection Syndrome: One-Year Follow-up. Diseases of the Colon and Rectum, 2020, 63, 1602-1609.	1.3	13
36	Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. Future Oncology, 2020, 16, 1433-1439.	2.4	14

#	Article	IF	Citations
37	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. OncoImmunology, 2019, 8, e1617588.	4.6	41
38	Clinical significance of ROS1 5â€™ deletions in non-small cell lung cancer. Lung Cancer, 2019, 135, 88-91.	2.0	10
39	Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect. Journal of Thoracic Oncology, 2019, 14, e145-e146.	1.1	12
40	The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers. Cancer Treatment Reviews, 2019, 79, 101887.	7.7	49
41	Emerging therapies in malignant pleural mesothelioma. Critical Reviews in Oncology/Hematology, 2019, 144, 102815.	4.4	17
42	Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC. Journal of Thoracic Oncology, 2019, 14, 141-143.	1.1	2
43	Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. Frontiers in Oncology, 2019, 9, 179.	2.8	34
44	Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. Oncologist, 2019, 24, e1228-e1231.	3.7	30
45	Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. Oncologist, 2019, 24, e1165-e1171.	3.7	35
46	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591988554.	3.2	25
47	MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report. Translational Oncology, 2019, 12, 116-121.	3.7	37
48	Immune-mediated cholangitis: is it always nivolumabâ€™s fault?. Cancer Immunology, Immunotherapy, 2018, 67, 1325-1327.	4.2	5
49	Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role?. European Journal of Cancer, 2018, 95, 127-129.	2.8	6
50	A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event. Investigational New Drugs, 2018, 36, 144-146.	2.6	42
51	Osteoblastic bone response mimicking bone progression during treatment with pembrolizumab in advanced cutaneous melanoma. Anti-Cancer Drugs, 2018, 29, 1026-1029.	1.4	4
52	Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. Journal of Thoracic Disease, 2018, 10, S304-S310.	1.4	14
53	Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding. Journal of Thoracic Oncology, 2018, 13, e247-e248.	1.1	1
54	A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy. Cancers, 2018, 10, 355.	3.7	22

#	Article	IF	Citations
55	Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer. Lung Cancer, 2018, 126, 9-14.	2.0	29
56	Heterotopic auxiliary segment 2â€“3 liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases. Surgery, 2018, 164, 601-603.	1.9	20
57	Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma. JAMA Oncology, 2018, 4, 1189.	7.1	53
58	Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Journal of Clinical Oncology, 2017, 35, 1281-1287.	1.6	126
59	Evaluation of the VeriStrat Â® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer, 2017, 109, 101-108.	2.0	25
60	MET DNA Alterations in NSCLCâ€”Letter. Clinical Cancer Research, 2016, 22, 3697-3698.	7.0	1
61	11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1971-1979.	6.4	79
62	11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 84-91.	6.4	77
63	Concurrent Chemoradiation with Concomitant Boost in Locally Advanced Rectal Cancer: A Phase II Study. Anticancer Research, 2016, 36, 4081-7.	1.1	7
64	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncology, The, 2015, 16, 897-907.	10.7	389
65	Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).. Journal of Clinical Oncology, 2015, 33, 8002-8002.	1.6	8
66	Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.. Journal of Clinical Oncology, 2015, 33, 8100-8100.	1.6	0
67	Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer, 2014, 83, 265-271.	2.0	39
68	Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials. European Journal of Cancer, 2014, 50, 2211-2218.	2.8	46
69	Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis. Journal of the National Cancer Institute, 2007, 99, 847-857.	6.3	574
70	Short Hydration Regimen and Nephrotoxicity of Intermediate to High-Dose Cisplatin-Based Chemotherapy for Outpatient Treatment in Lung Cancer and Mesothelioma. Tumori, 2007, 93, 138-144.	1.1	65
71	Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer, 2006, 107, 2842-2849.	4.1	98
72	Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update. Oncologist, 2004, 9, 4-13.	3.7	478